CoChat
Sign Up
Cited by 67

The DOI matches its Crossref record.

A Network-Based Pharmacology Study of the Herb-Induced Liver Injury Potential of Traditional Hepatoprotective Chinese Herbal Medicines

Hong, Ming, Li, Sha, Tan, Hor, Cheung, Fan, Wang, Ning, Huang, Jihan, Feng, Yibin·2017·Molecules
DOI 10.3390/molecules22040632PMC PMC6154655
Open this paper in CoChat — free account

Abstract

Herbal medicines are widely used for treating liver diseases and generally regarded as safe due to their extensive use in Traditional Chinese Medicine practice for thousands of years. However, in recent years, there have been increased concerns regarding the long-term risk of Herb-Induced Liver Injury (HILI) in patients with liver dysfunction. Herein, two representative Chinese herbal medicines: one—Xiao-Chai-Hu-Tang (XCHT)—a composite formula, and the other—Radix Polygoni Multiflori (Heshouwu)—a single herb, were analyzed by network pharmacology study. Based on the network pharmacology framework, we exploited the potential HILI effects of XCHT and Heshouwu by predicting the molecular mechanisms of HILI and identified the potential hepatotoxic ingredients in XCHT and Heshouwu. According to our network results, kaempferol and thymol in XCHT and rhein in Heshouwu exhibit the largest number of liver injury target connections, whereby CASP3, PPARG and MCL1 may be potential liver injury targets for these herbal medicines. This network pharmacology assay might serve as a useful tool to explore the underlying molecular mechanism of HILI. Based on the theoretical predictions, further experimental verification should be performed to validate the accuracy of the predicted interactions between herbal ingredients and protein targets in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules22040632

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 51

  1. Shehu, 2017, Mechanisms of drug-induced hepatotoxicity, Clin. Liver. Dis., 21, 35, 10.1016/j.cld.2016.08.002 · DOI
  2. Liao, 2015, Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients, Liver Int., 35, 2595, 10.1111/liv.12847 · DOI
  3. Amagaya, 1989, Treatment of chronic liver injury in mice by oral administration of xiao-chai-hu-tang, J. Ethnopharmacol., 25, 181, 10.1016/0378-8741(89)90020-2 · DOI
  4. Tajiri, 1991, Effect of sho-saiko-to(xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease, Am. J. Chin. Med., 19, 121, 10.1142/S0192415X91000193 · DOI
  5. Deng, 2011, A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients, J. Ethnopharmacol., 136, 83, 10.1016/j.jep.2011.04.008 · DOI
  6. Itoh, 1995, Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang), Dig. Dis. Sci., 40, 1845, 10.1007/BF02212712 · DOI · Paper page
  7. Hsu, 2006, Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang, J. Chin. Med. Assoc., 69, 86, 10.1016/S1726-4901(09)70119-4 · DOI
  8. Liu, 2000, Experimental study on inhibitory effect of xiaochaihu decoction on duck hepatitis B virus, Zhongguo Zhong Xi Yi Jie He Za Zhi, 20, 853
  9. Sun, 2016, Nuclear factor Kappa B activation and peroxisome proliferator-activated receptor transactivational effects of chemical components of the roots of Polygonum multiflorum, Pharmacogn. Mag., 12, 31, 10.4103/0973-1296.176019 · DOI
  10. Lin, 2015, Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review, J. Ethnopharmacol., 159, 158, 10.1016/j.jep.2014.11.009 · DOI
  11. Jung, 2011, Drug-induced liver injury: Twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum Thunb, Gut. Liver, 5, 493, 10.5009/gnl.2011.5.4.493 · DOI · Paper page
  12. Lei, 2015, Liver damage associated with Polygonum multiflorum Thunb.: A systematic review of case reports and case series, Evid. Based Complement. Alternat. Med., 2015, 459749, 10.1155/2015/459749 · DOI
  13. Li, H., Wang, X., Liu, Y., Pan, D., Wang, Y., Yang, N., Xiang, L., Cai, X., and Feng, Y. (2016). Hepatoprotection and hepatotoxicity of Heshouwu, a Chinese medicinal herb: Context of the paradoxical effect. Food Chem. Toxicol. · DOI
  14. Wu, 2012, Toxicity of raw and processed roots of Polygonum multiflorum, Fitoterapia, 83, 469, 10.1016/j.fitote.2011.12.012 · DOI · Paper page
  15. Lee, 2012, Hepatoprotection of emodin and Polygonum multiflorum against CCl4-induced liver injury, Pharm. Biol., 50, 351, 10.3109/13880209.2011.604335 · DOI
  16. Ke, 2015, Study on effective substance basis and molecular mechanism of Qigui Tongfeng tablet using network pharmacology method, Zhongguo Zhong Yao Za Zhi, 40, 2837
  17. James, 2001, Evaluation of occult acetaminophen hepatotoxicity in hospitalized children receiving acetaminophen, Clin. Pediatr., 40, 243, 10.1177/000992280104000501 · DOI
  18. Danhof, 2016, Systems pharmacology-Towards the modeling of network interactions, Eur. J. Pharm. Sci., 94, 4, 10.1016/j.ejps.2016.04.027 · DOI
  19. Linton, 2005, First-in-class pan caspase inhibitor developed for the treatment of liver disease, J. Med. Chem., 48, 6779, 10.1021/jm050307e · DOI
  20. Schrieber, 2008, The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity, Drug Metab. Dispos., 36, 1909, 10.1124/dmd.107.019604 · DOI
  21. Wang, 2003, Tumor necrosis factor-α, caspase-3 expression and hepatocyte apoptosis in fulminanting hepatic failure, Zhonghua Nei Ke Za Zhi, 42, 566
  22. Liang, 2015, Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury, World J. Gastroenterol., 21, 5271, 10.3748/wjg.v21.i17.5271 · DOI
  23. Yang, 2003, Liver injury during acute pancreatitis: The role of pancreatitis-associated ascitic fluid (PAAF), p38-MAPK, and caspase-3 in inducing hepatocyte apoptosis, J. Gastrointest. Surg., 7, 200, 10.1016/S1091-255X(02)00134-8 · DOI
  24. Zhu, 2015, Effects of fenofibrate on hepatocyte apoptosis in nonalcoholic fatty liver, Zhonghua Gan Zang Bing Za Zhi, 23, 688
  25. Oda, 2016, Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice, J. Appl. Toxicol., 37, 545, 10.1002/jat.3388 · DOI
  26. Wells, 1988, Deficiency in bilirubin UDP-glucuronyl transferase as a genetic determinant of acetaminophen toxicity, J. Pharmacol. Exp. Ther., 247, 323, 10.1016/S0022-3565(25)20031-3 · DOI
  27. Li, 2016, Identification of human UDP-glucuronosyltransferase 1A4 as the major isozyme responsible for the glucuronidation of 20(S)-protopanaxadiol in human liver microsomes, Int. J. Mol. Sci., 17, 205, 10.3390/ijms17030205 · DOI
  28. Lv, 2016, Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases, Toxicol. Appl. Pharmacol., 301, 42, 10.1016/j.taap.2016.04.009 · DOI
  29. Fujiwara, 2015, UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin, Drug Metab. Pharmacokinet., 30, 82, 10.1016/j.dmpk.2014.09.003 · DOI
  30. Kessler, 2002, Glucuronidation of acetaminophen catalyzed by multiple rat phenol UDP-glucuronosyltransferases, Drug Metab. Dispos., 30, 324, 10.1124/dmd.30.3.324 · DOI
  31. 2015, Plasma levels of Matrix Metalloproteinase (MMP)-2, MMP-9 and tumor necrosis factor-α in chronic hepatitis C virus patients, Open Microbiol. J., 9, 136, 10.2174/1874285801509010136 · DOI
  32. Eldred, 2012, MMP2 activity is critical for TGFβ2-induced matrix contraction--implications for fibrosis, Investig. Ophthalmol. Vis. Sci., 53, 4085, 10.1167/iovs.12-9457 · DOI
  33. Peng, 2013, Anti-fibrotic effect of Cordyceps sinensis polysaccharide: Inhibiting HSC activation, TGF-β1/Smad signalling, MMPs and TIMPs, Exp. Biol. Med., 238, 668, 10.1177/1535370213480741 · DOI
  34. Lee, 2003, Differential role of p38 in IL-1α induction of MMP-9 and MMP-13 in an established liver myofibroblast cell line, J. Biomed. Sci., 10, 757
  35. Leveille, 2016, Estrogen signals through peroxisome proliferator-activated receptor-γ coactivator 1α to reduce oxidative damage associated with diet-induced fatty liver disease, Gastroenterology, 152, 243
  36. Gawrieh, 2012, Genetic variation in the peroxisome proliferator activated receptor-γ gene is associated with histologically advanced NAFLD, Dig. Dis. Sci., 57, 952, 10.1007/s10620-011-1994-2 · DOI
  37. Fang, 2015, Cobalt protoporphyrin protects the liver against apoptosis in rats of brain death, Clin. Res. Hepatol. Gastroenterol., 39, 475, 10.1016/j.clinre.2014.11.003 · DOI
  38. Hikita, 2015, Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis, Cancer Prev. Res., 8, 693, 10.1158/1940-6207.CAPR-15-0022-T · DOI
  39. Vick, 2009, Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes, Hepatology, 49, 627, 10.1002/hep.22664 · DOI
  40. Tian, 2011, ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints, Mol. Pharm., 8, 841, 10.1021/mp100444g · DOI
  41. Saghir, S.A. (2009). Determination of ADME and bioavailability following intravenous, oral, and dermal routes of exposure. Curr. Protoc. Toxicol. · DOI
  42. Ru, 2014, TCMSP: A database of systems pharmacology for drug discovery from herbal medicines, J. Cheminform., 6, 13, 10.1186/1758-2946-6-13 · DOI
  43. Wang, 2013, Systems pharmacology uncovers Janus functions of botanical drugs: Activation of host defense system and inhibition of influenza virus replication, Integr. Biol., 5, 351, 10.1039/c2ib20204b · DOI
  44. Pereira, 2015, Dissecting stromal-epithelial interactions in a 3D in vitro cellularized intestinal model for permeability studies, Biomaterials, 56, 36, 10.1016/j.biomaterials.2015.03.054 · DOI
  45. Yadav, 2014, A knowledge-based approach for identification of drugs against vivapain-2 protein of Plasmodium vivax through pharmacophore-based virtual screening with comparative modelling, Appl. Biochem. Biotechnol., 173, 2174, 10.1007/s12010-014-1023-y · DOI
  46. May, 2015, In silico database screening of potential targets and pathways of compounds contained in plants used for psoriasis vulgaris, Arch. Dermatol. Res., 307, 645, 10.1007/s00403-015-1577-8 · DOI
  47. Calvert, 2016, A network pharmacology approach reveals new candidate caloric restriction mimetics in C, elegans. Aging Cell, 15, 256, 10.1111/acel.12432 · DOI
  48. Li, X., Wu, L., Liu, W., Jin, Y., Chen, Q., Wang, L., Fan, X., Li, Z., and Cheng, Y. (2014). A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action. PLoS ONE, 9. · DOI
  49. Liu, 2014, Network pharmacology study on major active compounds of siwu decoction analogous formulae for treating primary dysmenorrhea of gynecology blood stasis syndrome, Zhongguo Zhong Yao Za Zhi, 39, 113
  50. Lv, 2014, Network pharmacology-based prediction and verification of the molecular targets and pathways for schisandrin against cerebrovascular disease, Chin. J. Nat. Med., 12, 251
  51. Yu, 2017, Network pharmacology-based identification of key pharmacological pathways of Yin-Huang-Qing-Fei capsule acting on chronic bronchitis, Int. J. Chron. Obstruct. Pulmon. Dis., 12, 85, 10.2147/COPD.S121079 · DOI

Cited by

Sorted by citations

See all 67

Metadata

Authors
Hong, M., Li, S., Tan, H., Cheung, F., Wang, N., Huang, J., & Feng, Y.
Affiliations
  • School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
  • Shanghai University of Traditional Chinese Medicine, Shanghai, China
ORCID
Huang, Jihan
Venue
Molecules
Publisher
MDPI AG
Published
2017-04-14
Volume
22
Issue
4
Pages
632
ISSN
1420-3049
DOI
10.3390/molecules22040632
PMC
PMC6154655
Cited by
67
References
0
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review